Search results for: “16”

Most recent guideline publication: The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022) Updates since publication: none Tables provided in the main manuscript of the guideline: Table 1. Assignment of predicted SLCO1B1, ABCG2, and CYP2C9 likely phenotype based on genotype Table 2. Dosing recommendations for statins…

Guideline overview presentation Most recent guideline publication: Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022) Tables  provided in the main manuscript of the guideline: Table 1. Assignment of predicted G6PD phenotype based on genotype Table 2. Drug-specific risk level and associated strength of recommendation for…

Kelly E. Caudle, PharmD, PhD, BCPS, FCCP CPIC Co-PI/Director, Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN Dr. Caudle received her Pharm.D. and Ph.D. from The University of Tennessee Health Science Center and completed an ASHP-accredited PGY2 residency at Le Bonheur Children’s Hospital in Memphis, TN. She is also a board‐certified Pharmacotherapy…

In 2016, CPIC led a consensus effort to standardize terms for clinical pharmacogenetic tests. The goal of the project was to create standardized terms for pharmacogenetic allele function and phenotypes to be used in CPIC guidelines (specifically Tables 1 and 2) and in the larger pharmacogenetics community (Term Standardization Part 1). However, additional standardization opportunities…

Goal and Focus A formal working group within CPIC, PharmGKB, PharmVar, and the PGRN was formed in 2018 to focus on the dissemination of resources available for pharmacogenetic implementation such as CPIC guidelines, PharmGKB, PGRN and PharmVar resources, and implementation strategies of pharmacogenetics. The goal of the CPIC Dissemination Working Group is to support the…

Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine (February 2019) Updates since publication: October 2019: CYP2D6 genotype to phenotype translation changes: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype across guidelines (i.e. CPIC and DPWG) and between clinical genetic…

Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016) Updates since publication: October 2019: CYP2D6 genotype to phenotype translation changes: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype across guidelines (i.e. CPIC and DPWG)…

Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Voriconazole Therapy (December 2016) Updates since publication: No updates on dosing recommendations since publication. Tables provided in the main manuscript of the guideline: Table 1. Assignment of likely CYP2C19 phenotype based on genotypes Table 2. Dosing recommendations for voriconazole based on CYP2C19…

CPIC’s therapeutic recommendations are based on weighing the evidence from a combination of preclinical functional and clinical data, as well as on some existing disease-specific consensus guidelines. Some of the factors that are taken into account in evaluating the evidence supporting therapeutic recommendations include: in vivo pharmacokinetic and pharmacodynamic data, in vitro enzyme activity of…